U.S. Markets open in 5 hrs 26 mins

Edgewise Therapeutics, Inc. (EWTX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
8.08+0.12 (+1.51%)
At close: 04:00PM EDT
8.08 0.00 (0.00%)
After hours: 04:02PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close7.96
Bid7.70 x 1100
Ask9.00 x 1100
Day's Range7.80 - 8.17
52 Week Range5.41 - 24.30
Avg. Volume241,806
Market Cap398.31M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-1.43
Earnings DateNov 10, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est25.00
  • Benzinga

    RBC Capital Says This Dystrophy Stock 'Is Worth A Look'

    RBC Capital says Edgewise Therapeutics Inc's (NASDAQ: EWTX) interim results from the ARCH study of EDG-5506 in Becker Muscular Dystrophy (BMD) improve reward/risk into October functional readout at 15 mg, which can help further de-risk the asset into the phase 2 BMD and Duchenne muscular dystrophy (DMD) studies. The analysts believe stable patient NSAAs in October readout can potentially drive shares up 100% and further improve the setup into 2Q23 placebo-controlled randomized DMD readout and 2H

  • Benzinga

    Edgewise's Dystrophy Candidate Lowers Muscle Damage Biomarkers

    Edgewise Therapeutics Inc (NASDAQ: EWTX) announced 2-month interim results from the ARCH study of EDG-5506 in adults with Becker Muscular Dystrophy (BMD). EDG-5506 was well-tolerated with no discontinuations or dose reductions. The most common adverse events observed at the 10 mg dose were dizziness (17%) and somnolence (17%). These were generally transient and typically observed in the first few days of dosing. All patients have subsequently been dose-escalated to 15 mg daily as per protocol. R

  • Business Wire

    Edgewise Therapeutics Announces Positive 2-Month Interim Results from the ARCH Open Label Study of EDG-5506 in Adults with Becker Muscular Dystrophy (BMD)

    BOULDER, Colo., June 20, 2022--Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for the treatment of rare muscle disorders, announced today positive 2-month interim results from the ongoing ARCH study, an open label, single-center study assessing the safety, tolerability, impact on muscle damage biomarkers, and pharmacokinetics (PK) of EDG-5506 in adults with BMD. EDG-5506 is an orally admi